Federal regulators have issued a warning to blood-testing startup Theranos, saying some of the Silicon Valley company’s testing procedures do not meet standards designed to protect patients.
Inspectors for the Centers for Medicare and Medicaid Services sent a letter to Theranos, citing five deficiencies at a laboratory run by the privately held company. In the Jan. 25 letter, inspectors say that some of the problems “pose immediate jeopardy to patient health and safety.”
Founded by CEO Elizabeth Holmes, Theranos has raised millions by pitching its technology as a cheaper, faster way to run dozens of blood tests.
The company said in a statement that the inspection took place at a Newark, California, laboratory last year and doesn’t reflect its current practices. The company says it is taking additional corrective steps.
